[DAY1] 2월 7일 프로그램Plenary Sessions Details
Good Health & Drug Pricing
Title: For Universal Health Coverage: Increasing Pharmaceutical Accessibility for All
Wednesday, February 7 at 13:00-14:30
Access to quality and affordable medicine is among the most integral factors in achieving universal health coverage. One of the most significant barriers to achieving universal health coverage is the increasing difficulty in access to pharmaceuticals. Not only is the rising price a significant cause of increase in health care expenditure, it also poses a heavy burden on insurers and providers who want to manage medical expenses at an appropriate level. The fundamental competency in the pharmaceutical industry is the process of research and development, endeavors that require enormous time and resources yet yield low productivity. Thus, the industry imposes heavy prices on ‘successful’ projects to compensate. This burden on price hampers the access to healthcare, especially for the developing countries. Cost and resources for medical innovation must be respected and encouraged. However, a balance which satisfies both the innovation and accessibility, that of sustainable innovation, must be found. Due to the increasing price of pharmaceuticals, customers – both private and public – experience economic stress that hinders access to effective and universal health coverage. Patients choose not to follow upon drug prescription due to cost, and in certain instances, entire communities cannot afford to produce or purchase health services. In order for healthcare systems to be sustainable and universally beneficial, actions should be taken to address the increasing costs of healthcare.
Possible questions for discussion:
1. What type of influence or reference can be used in understanding the mechanics of access to medicine? Especially consider factors of intellectual property rights as factors in pricing. How is a pharmaceutical's value to an individual, industry, and society reflected in its pricing?
2. What factors must be considered when establishing a global consensus on pharmaceutical pricing? At what point should the balance of innovation - sustainability - and productivity be met?
3. How can innovation in pharmaceutical pricing help achieve not only be universal health coverage, but also sufficiently elicit pharmaceutical research and development? Consider especially the situations of low- and low-middle-income countries. What methods should be implemented to analyze its process and impact better?
- James Chau, CCTV Anchor, UNAIDS Goodwill Ambassador (Moderator)
- Myongsei Sohn, Director of IGEE at Yonsei University
- Arrey Obenson, Secretary General, Junior Chamber International
- Ed Futa, Former General Secretary of Rotary International
- Mahmoud Mohieldin, Senior Vice President of World Bank Group (TBC)
- Representative of Johnson & Johnson or Celltrion (TBC)